The “Privacy Shield” comes into force: more protection in the transfer of personal data from the European Union to the US

Commission Decision of 12 July 2016, regarding the suitability of the Privacy Shield between the European Union and the US

Eduard Rodellar

CAPSULAS Nº 173

On 6 October 2015, the Court of Justice of the European Union (CJEU) annulled Commission Decision 2000/520/EC, on the suitability of the safe harbour principles, known as the “Safe Harbour Agreement”. Previously, it was considered that merely by means of accession to said Agreement, US companies receiving personal data from Europe complied with an appropriate...
Read More

An indefinite term distribution agreement may be terminated if the distributor refuses to revise its conditions

Judgment of the Supreme Court of 30 May 2016

Verónica Carías

CAPSULAS Nº 173

Background In 1996, a beverages manufacturer and a distribution company entered into an exclusive distribution agreement for Spain and Andorra. The conditions of exclusivity applied to both parties, in such a way that the distributor committed to exclusively purchase certain product from the manufacturer for distribution within the referred countries and the manufacturer committed to...
Read More

The party having to pay a fee for a licence to use a patent must pay the fee even in the event that such patent is annulled or not infringed

Judgment of the European Court of Justice of 7 July 2016 in Case C-567/14

Verónica Carías

CAPSULAS Nº 173

Background In 1992, Behringwerke AG and Genentech entered into a licence agreement under which the former granted the latter a non-exclusive worldwide licence to use a specific trigger that increases the efficiency of the cellular process employed to produce proteins. The licensed technology was protected by two US patents and one European patent. As compensation...
Read More

In the acquisition of companies, clientèle or know-how, non-competition obligations may apply even though they are not expressly agreed

Judgment of the Civil Division of the Supreme Court of 9 May 2016

Francisco Aránega

CAPSULAS Nº 173

Background The judgment in question concerns a claim brought by the purchasers of the shares of a company called Aerlyper, on the basis they understood that the sellers had failed to comply with a non-competition commitment established in the purchase agreement concerning said shares. Specifically, the purchasers claimed that the sellers failed to comply with...
Read More

Hablamos de… Riesgo compartido

Jordi Faus

EL GLOBAL

Hace dos semanas participé en el IV Encuentro sobre Gestión en Farmacia Hospitalaria para Directivos, celebrado en la UIMP bajo la dirección compartida de Miguel Ángel Calleja, Jon Iñaki Betolaza y Antoni Gilabert. Las ideas, en cualquier evento donde participan estas personas, fluyen a un ritmo interesante. Además, el formato del encuentro, que incluía dos...
Read More

The medicinal product in Courts in the year 2015

Jordi Faus, Mercè Maresma

Comunicaciones en Propiedad Industrial y Derecho de la Competencia de la Fundación CEFI, número 78, Mayo-Agosto 2016

2015 has been a year full of important judgments in the field of medicinal products. This article aims to explain the most important decisions in order to give the reader a perspective on developments and clarifications that have been incorporated into the regulation of medicinal products through recent case law in Spanish and European courts....
Read More

Si Vueling vendiese medicamentos…

Jordi Faus

EL GLOBAL

La semana pasada se cumplió el plazo para publicar las transferencias de valor con origen en la industria farmacéutica y destino en las organizaciones y profesionales sanitarios. Comentando el tema con personas ajenas al sector, no pocas se preguntaban si las compañías farmacéuticas no se habrían pasado de frenada. Es una reflexión legítima desde el...
Read More

Efectos secundarios del ‘Brexit’: la sede de la EMA

Jordi Faus

EL GLOBAL

Hace dos semanas, concluí esta columna, dedicada a qué podría suceder en el mundo del medicamento si ganaba la opción del “leave” en el referéndum británico, con estas palabras: “…si gana la opción del leave el impacto en el ámbito del medicamento y del derecho farmacéutico será muy relevante. Depende de ellos, y si deciden...
Read More

“Brexit” and medicinal products

Some relevant issues in the field of pharmaceutical law after the option to “leave” has won the referendum of 23 of June

Jordi Faus

CAPSULAS Nº 172

It is Friday June 24th, and while writing this CAPSULAS from London, the first thing that comes to my mind is what I wrote in El Global ten days ago: the most important voting this month of June of 2016 is not the General Election that will take place in Spain on Sunday 26th; but...
Read More

Challenging the specifications of a tender does not represent an impediment to participation

Ruling 17/2016 of 11 February 2016, of the Catalan Court of Public Sector Contracts

Xavier Moliner

CAPSULAS Nº 171

Background The ruling of the Catalan Court of Public Sector Contracts addressed below was issued as part of a special appeal on contracting brought against the specifications of a tender procedure that sought to award a contract for the supply of medicinal products. The appeal brought challenged, amongst other aspects, a very common clause in...
Read More

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información. ACEPTAR

Aviso de cookies